DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection

Vaccine

Volumn 25, Issue 22, 2007, Pages 4502-4509

  Carter, K C ^a   Henriquez, F L ^b   Campbell, S A ^c   Roberts, C W ^a   Nok, A ^d   Mullen, A B ^a   McFarlane, E ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^c EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^d AHMADU BELLO UNIVERSITY   (Nigeria)

Author keywords

Gamma glutamylcysteine synthetase; Leishmania donovani; Vaccination

Indexed keywords

CONCANAVALIN A; DNA VACCINE; GLUTAMATE CYSTEINE LIGASE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; NITRILE; PLASMID VECTOR;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; GRANULOMA; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIBODIES, PROTOZOAN; CRICETINAE; FEMALE; GLUTAMATE-CYSTEINE LIGASE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MESOCRICETUS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTOZOAN VACCINES; SEQUENCE ANALYSIS, DNA; VACCINATION; VACCINES, DNA;

EID: 34247605954     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.03.014     Document Type: Article

References (30)

1. Murray H.W., and Nathan C.F. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 189 (1999) 741-746
2. Lehmann J., Enssle K.H., Lehmann I., Emmendorfer A., and Lohmann-Matthes M.L. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 20 (2000) 63-77
3. Nielsen H.V., Di Cristina M., Beghetto E., Spadoni A., Petersen E., and Gargano N. Toxoplasma gondii: DNA vaccination with bradyzoite antigens induces protective immunity in mice against oral infection with parasite cysts. Exp Parasitol 112 (2006) 274-279
4. Scorza T., Grubb K., Smooker P., Rainczuk A., Proll D., and Spithill T.W. Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine. Infect Immun 73 (2005) 2974-2985
5. Rafati S., Ghaemimanesh F., and Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, protein/protein and DNA/protein) against Leishmania major infection using signal peptidase type I in BALB/c mice. Vaccine 24 (2006) 3290-3297
6. Smooker P.M., Steeper K.R., Drew D.R., Strugnell R.A., and Spithill T.W. Humoral responses in mice following vaccination with DNA encoding glutathione S-transferase of Fasciola hepatica: effects of mode of vaccination and the cellular compartment of antigen expression. Parasite Immunol 21 (1999) 357-364
7. Aguilar-Be I., da Silva Zardo R., Paraguai de Souza E., Borja-Cabrera G.P., Rosado-Vallado M., Mut-Martin M., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73 (2005) 812-819
8. Gamboa-Leon R., Paraguai de Souza E., Borja-Cabrera G.P., Santos F.N., Myashiro L.M., Pinheiro R.O., et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine 24 (2006) 4863-4873
9. Campos-Neto A., Webb J.R., Greeson K., Coler R.N., Skeiky Y.A., and Reed S.G. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun 70 (2002) 2828-2836
10. Shalaby K.A., Yin L., Thakur A., Christen L., Niles E.G., and LoVerde P.T. Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes. Vaccine 22 (2003) 130-136
11. Carter K.C., Sundar S., Spickett C., Pereira O.C., and Mullen A.B. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob Agents Chemother 47 (2003) 1529-1535
12. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 162 (1987) 156-159
13. Henriquez F.L., Nickdel M.B., McLeod R., Lyons R.E., Lyons K., Dubremetz J.F., et al. Toxoplasma gondii dense granule protein 3 (GRA3) is a type I transmembrane protein that possesses a cytoplasmic dilysine (KKXX) endoplasmic reticulum (ER) retrieval motif. Parasitology 131 (2005) 169-179
14. Cohen S.N., Chang A.C., and Hsu L. Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R factor DNA. Proc Natl Acad Sci USA 69 (1972) 2110-2114
15. Murray H.W. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol 82 (2001) 249-267
16. Carter K.C., Hutchison S., Boitelle A., Murray H.W., Sundar S., and Mullen A.B. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy. Parasitology 131 (2005) 747-757
17. Bradley D.J. Regulation of Leishmania populations within the host. II. Genetic control of acute susceptibility of mice to Leishmania donovani infection. Clin Exp Immunol 30 (1977) 130-140
18. Sukumaran B., Tewary P., Saxena S., and Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21 (2003) 1292-1299
19. Melby P.C., Yang J., Zhao W., Perez L.E., and Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69 (2001) 4719-4725
20. Alexander J., and Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 99 (2005) 17-23
21. Reiner N.E. Host-parasite relationship in murine leishmaniasis: pathophysiological and immunological changes. Infect Immun 38 (1982) 1223-1230
22. Kafetzis D.A. An overview of paediatric leishmaniasis. J Postgrad Med 49 (2003) 31-38
23. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 (2005) 633-639
24. Engwerda C.R., Murphy M.L., Cotterell S.E., Smelt S.C., and Kaye P.M. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol 28 (1998) 669-680
25. Wilson M.E., Jeronimo S.M., and Pearson R.D. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38 (2005) 147-160
26. Taylor A.P., and Murray H.W. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med 185 (1997) 1231-1239
27. Banduwardene R., Mullen A.B., and Carter K.C. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations. Int J Immunopharmacol 19 (1997) 195-203
28. Khamesipour A., Rafati S., Davoudi N., Maboudi F., and Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 123 (2006) 423-438
29. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 (2005) 7160-7171
30. Mendez S., Gurunathan S., Kamhawi S., Belkaid Y., Moga M.A., Skeiky Y.A., et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166 (2001) 5122-5128